Stock analysts at Rodman & Renshaw began coverage on shares of TuHURA Biosciences (NASDAQ:HURA – Get Free Report) in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Rodman & Renshaw’s price objective suggests a potential upside of 173.63% from the company’s previous close.
Separately, Maxim Group began coverage on shares of TuHURA Biosciences in a report on Tuesday, November 5th. They set a “buy” rating and a $15.00 target price for the company.
Check Out Our Latest Report on TuHURA Biosciences
TuHURA Biosciences Trading Down 8.2 %
TuHURA Biosciences Company Profile
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Read More
- Five stocks we like better than TuHURA Biosciences
- What is the Dogs of the Dow Strategy? Overview and Examples
- Hidden Gems: 2 Green Energy Stocks Fueling the Future
- How to Most Effectively Use the MarketBeat Earnings Screener
- Top 3 High-ROIC Stocks to Supercharge Your Wealth Compounding
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Aurora Innovation’s Driverless Tech Is Driving Investor Buzz
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
